That doesn’t automatically make them buys. But it does make them worth a closer look.<\/p>\n
Here are five I think stand out. <\/p>\n Image source: Getty Images<\/p>\n<\/figcaption><\/figure>\n Xero has gone from market darling to market concern in a relatively short period of time. But I still see a global accounting platform with strong positioning among small and medium-sized businesses. <\/p>\n It continues to grow its subscriber base and expand internationally, particularly in markets like the UK and North America.<\/p>\n The key for me is that accounting software is deeply embedded in operations. Once a business is using Xero, switching is difficult.<\/p>\n The share price may be down significantly, but the long-term growth opportunity still looks intact.<\/p>\n Pro Medicus is a very different kind of tech company. It operates in medical imaging software, supplying hospitals and healthcare providers with high-performance diagnostic tools.<\/p>\n What stands out is its reputation and track record. The company has consistently won large contracts, particularly in the United States.<\/p>\n Healthcare isn’t a short-term trend. Demand for imaging and diagnostics continues to grow, supported by ageing populations and increasing healthcare needs.<\/p>\n After a sharp share price decline, I see an opportunity to buy a high-quality business with strong long-term potential at a better price.<\/p>\n TechnologyOne is one of the quieter success stories on the ASX. It provides enterprise software to government agencies, universities, and large organisations, with a strong focus on recurring revenue<\/a>.<\/p>\n What I like here is the consistency. The company has steadily grown its earnings over time while transitioning customers to its cloud platform.<\/p>\n That creates visibility and predictability, which is valuable in any environment.<\/p>\n It may not attract the same attention as some other tech names, but I think its reliability is part of what makes it appealing.<\/p>\n Life360 brings a different type of growth exposure. Its app connects families through location sharing and safety features, and it has been building a large global user base.<\/p>\n The business is now focused on monetisation, converting users into paying subscribers, and expanding its product offering.<\/p>\n There’s still execution risk here, particularly with recent acquisitions<\/a>, but I think the opportunity is significant if it continues to scale successfully.<\/p>\n With the share price down heavily, the market appears to be questioning that path, which is where I think potential upside can emerge.<\/p>\n Catapult sits at the heart of sports and technology. It provides performance analytics and wearable technology to professional sports teams around the world.<\/p>\n What I find interesting is its niche positioning. It has built strong relationships across elite sports leagues like the NBA, EPL, and NFL, which gives it a level of defensibility.<\/p>\n The business has been moving toward a recurring revenue model, which could improve stability over time.<\/p>\n Like many ASX tech stocks, it hasn’t been spared from the recent sell-off, but the long-term opportunity in sports analytics remains.<\/p>\n When markets turn against a sector, everything tends to fall together. <\/p>\n Right now, ASX tech looks to be in that phase, with Xero, Pro Medicus, TechnologyOne, Life360, and Catapult shares all being hit hard despite their long-term growth potential.<\/p>\n There’s no guarantee of a quick rebound. But for patient investors, I think this could be one of those once-in-a-decade periods where high-quality stocks are available at far more reasonable prices.<\/p>\n <\/a><\/strong> <\/a><\/p>\n","protected":false},"excerpt":{"rendered":" … group of high-quality ASX tech<\/span> stocks, many of them … is a very different kind of tech<\/span> company. It operates in … same attention as some other tech<\/span> names, but I think … provides performance analytics and wearable technology<\/span> to professional sports teams around …<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"","fifu_image_alt":"","footnotes":""},"categories":[1],"tags":[],"class_list":["post-133459","post","type-post","status-publish","format-standard","hentry","category-news","wpcat-1-id"],"_links":{"self":[{"href":"https:\/\/new7.shop\/zerocostfreehost\/index.php\/wp-json\/wp\/v2\/posts\/133459","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/new7.shop\/zerocostfreehost\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/new7.shop\/zerocostfreehost\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/new7.shop\/zerocostfreehost\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/new7.shop\/zerocostfreehost\/index.php\/wp-json\/wp\/v2\/comments?post=133459"}],"version-history":[{"count":0,"href":"https:\/\/new7.shop\/zerocostfreehost\/index.php\/wp-json\/wp\/v2\/posts\/133459\/revisions"}],"wp:attachment":[{"href":"https:\/\/new7.shop\/zerocostfreehost\/index.php\/wp-json\/wp\/v2\/media?parent=133459"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/new7.shop\/zerocostfreehost\/index.php\/wp-json\/wp\/v2\/categories?post=133459"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/new7.shop\/zerocostfreehost\/index.php\/wp-json\/wp\/v2\/tags?post=133459"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Pro Medicus Ltd (ASX: PME<\/a>)<\/strong><\/h2>\n
TechnologyOne Ltd (ASX: TNE<\/a>)<\/strong><\/h2>\n
Catapult Sports Ltd (ASX: CAT<\/a>)<\/strong><\/h2>\n
Foolish Takeaway<\/strong><\/h2>\n